Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + 5-FU Neoadjuvant Therapy for Esophageal SCC
NCT02033538Phase 2Withdrawn
- Sponsor
- Zhejiang University
- Start
- Jan 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang University. Primary endpoint: Response Rate at 2 months. Planned start Jan 2014; status: withdrawn.
02
Drugs
paclitaxel
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02033538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02033538.